(S (NP (JJ Recent) (JJ clinical) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (NN hormone) (NN therapy)) (PP (IN for) (NP (NN prostate) (NN cancer)))))) (VP (VBZ depends) (PP (IN on) (NP (NP (DT the) (NNS characteristics)) (PP (IN of) (NP (JJ individual) (NNS patients))))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN paper))) (, ,) (NP (PRP we)) (VP (VBP develop) (NP (DT a) (JJ computational) (NN framework)) (PP (IN for) (S (VP (VBG identifying) (NP (ADJP (NN patient) (HYPH -) (JJ specific)) (NML (NN androgen) (NN ablation)) (NN therapy) (NNS schedules)) (PP (IN for) (S (VP (VBG postponing) (NP (DT the) (JJ potential) (NN cancer) (NN relapse))))))))) (. .))
(S (NP (PRP We)) (VP (VBP model) (NP (NP (DT the) (NN population) (NNS dynamics)) (PP (IN of) (NP (NP (JJ heterogeneous) (NN prostate) (NN cancer) (NNS cells)) (PP (IN in) (NP (NN response)))))) (PP (IN to) (NP (NP (NN androgen) (NN suppression)) (PP (IN as) (NP (DT a) (JJ nonlinear) (NN hybrid) (NN automaton)))))) (. .))
(S (NP (DT The) (NNS results)) (VP (VP (VBP show) (SBAR (IN that) (S (NP (PRP$ our) (NNS methods)) (VP (VBP are) (VP (VBG promising)))))) (CC and) (VP (MD may) (VP (VB lead) (PP (IN to) (NP (NP (DT a) (JJ prognostic) (NN tool)) (PP (IN for) (NP (JJ personalized) (NN cancer) (NN therapy)))))))) (. .))
